尼日利亚的COVID-19后疫苗制造雄心:机遇和区域影响
Oyeronke Oyebanji1, Olufunke Falade2, Frederik Kristensen3
1London School of Hygiene and Tropical Medicine, London, United Kingdom.
Journal of public health in Africa
|March 11, 2026
概括
全球卫生紧急情况凸显了疫苗不平等,非洲面临着制造业的挑战. 尼日利亚在COVID-19后的当地疫苗生产方面取得了进展,但需要持续投资来克服持续的差距.
科学领域:
- 全球健康 全球健康
- 疫苗学 疫苗学 疫苗学
- 加强卫生系统 加强卫生系统
背景情况:
- 全球卫生紧急情况加剧了疫苗不平等,不成比例地影响低收入和中等收入国家 (LMICs).
- 在LMICs中普遍存在的疾病的有限市场价值阻碍了疫苗开发,巩固了全球健康差异.
- 非洲对疫苗制造能力的投资不足在疾病爆发期间增加了脆弱性.
研究的目的:
- 检查非洲疫苗公平的障碍.
- 批判性地分析尼日利亚COVID-19后的倡议,以建立当地疫苗制造生态系统.
主要方法:
- 战略计划,监管报告和伙伴关系公告的文档分析.
- 从与疫苗政策,监管和生产的利益相关者进行的关键信息人采访中获得的定性见解.
- 案例研究方法侧重于尼日利亚在更广泛的非洲疫苗制造领域.
主要成果:
- 尼日利亚已经制定了国家疫苗制造战略,确保了国际伙伴关系和融资承诺.
- 美国国家食品和药物管理和控制局 (NAFDAC) 已达到世界卫生组织 (WHO) 成熟度三级.
- 在研究和开发能力,劳动力发展,监管灵活性和基础设施方面仍然存在持续的差距.
结论:
- 尼日利亚可持续的疫苗制造需要对研发,政策改革,技能发展和区域合作进行长期投资.
- 应对系统性挑战对于维持疫苗制造在流行后的进展至关重要.
- 该研究为指导政策,国际伙伴关系和对尼日利亚疫苗部门的投资提供了见解.
相关概念视频
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
397
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
397
01:29Microorganisms in Medicine and Therapeutics
1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
01:28Preclinical Development: Overview
6.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.3K
01:30Cancer Vaccines
1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
333
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
333
01:20Modified-Release Drug Delivery Systems: Influencing Factors
99
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
99